Project executive summary

Problems addressed: The major problems addressed by vita sentry are the changes in arteriolar
behavior which was never monitored directly. Changes in arteriolar behavior means the reflex
response of the afferent arterioles to changes in blood pressure. Increased blood pressure increases
the tension in the vascular wall, and the vascular smooth muscle contracts. Similarly, decreased
blood pressure decreases the tension and the smooth muscle relaxes. Another problem highlighted
was that the present noninvasive technologies are the changes occurring in the vascular tone.

Solution: Vita sentry has developed a non-invasive optical technology known as bp24 that
measures the inner diameter, cross section, degree of change, and level of stiffness of small blood
vessels (arterioles). Bp24 is a wearable medical device for noninvasive, continuous and highly
accurate bp monitoring, specifically targeting patients with hypertension and inpatients.
Vita sentry’s proprietary core technology enables a unique approach that takes into account vascular
tone to calculate bp, rather than simply estimating it from measuring blood flow. The technology
monitors the peripheral vascular resistance for immediate diagnosis of many significant health
conditions such as hemorrhage and dehydration, change of arterial blood pressure, various stress
conditions, arrhythmia, diabetic foot issues, level of atherosclerosis, and more. Vita sentry aims to
bring a low-cost solution for diagnosing many health pathologies in the early stages.

Value proposition: Vita sentry aims to provide professional low-cost health and wellness
technology to worldwide customers. Vita sentry offers a proprietary technology which priovides
direct, non-invasive measurement of arteriolar. Other value additions of the technology provided by
vita sentry is the measurement of blood waves detected by 2 ppg at different time delays. This is a
unique algorithm of vita sentry for calculating the local arteriole’s diameter. Vita-sentry proprietary
novel and ground breaking technology is based on measurements of absolute physiological metrics
(amplitude and form independent), and thus enable us to estimate the absolute blood pressure with
minimal or no calibration. The customers get a continuous arterial blood pressure measurement.
One of the most unique feature offered to the customers is that, vita-sentry is in advanced process of
ip protection of its blood pressure solution.

Users/clients: Vita sentry has a huge user base ranging from private customers to fitness and sports
practitioners to medical technology manufacturers. Private customers can get solutions for early
diagnosis of dehydration in infants or seniors. Fitness and sports practitioners can get an effective
tool to track the real-time progress of their vascular conditions.
Market: Vita sentry has a global, huge volume market (2 b$ in 2014) subdivided into three
segments: Continuous BP monitoring, Holter monitors, Self BP monitoring. It is majorly targetting
global market of smart devices for hypertension. Veta sentry is focussing on BP centres, GP
managers, pharmacies and e-commerce retailers to expand the outreach of their product. Starting
from UK, vita sentry will target BP centres (100+ in UK) and GP managers. After uk, the product
will be also sold in in Germany and France, followed by Italy. Distribution channels will be scouted
among pharmacies and e-commerce - retailers.

Competitors: Vita sentry offers various competing solutions such as continuous bp monitoring, bp
trend, golden standard accuracy and overnight bp monitoring. It has various competitors like
Sphygmomanometer, Cuff Monitor by Omron, Project Zero 2.0 by Omron, cnap but it outshines all
its competitors through the uniques services it offers. Veta sentry offers continuous bp monitoring
and bp trend which is not offered by its competitors such as Sphygmomanometer and Cuff-based
BP monitor by Omron. It also provides overnight BP monitoring not offered by
Sphygmomanometer and Cuff-based BP monitor by Omron. Its products are wearable and not
intrusive which is not the situation in case of its competitors. Further, for Vita Sentry products no
patient training is required.

Business model: Since Vita sentry deals with smart devices that measure the hypertension, the
global market for these devices constitutes about 45% market share in the united states followed by
36% market share of Europe and as it can be observed that the revenue that will be generated by the
e-health systems are likely to reach 0.8b$ in 2020. The company will target the BP centres and GP
managers in UK which will soon be followed in countries like Germany, Italy and France.

Block diagram of supply chain: The block diagram cannot be created since the product is now in
the process of conversion of concept to product. Since functional data and safety measures are not
yet evaluated the supply chain diagram cannot be generated. Furthermore, the production is said to
start after ISO Certification and CE Mark.

Financial projections: The hypothesis taken by Vita Sentry is that a certain number of new retailers
(pharmacies independent or pertaining to a chain, and/or ecommerce retailers) will enter the market.
In the 1st year a total of 30 new retailers will enter, in the 2nd year 90 and in the 3rd year 170. The
total salesz for the 1 st year come to a total of 7200 units in the 1st year as 60units/ retailer sold each
quarter. Similarly, for the 2nd year the total units of sale would be 28800 units and for the 3rd year
the total sales would be 69600 units. The final price of the goods sold is 200 €/unit which will help
the company generate a remuneration of 1.4 million € in the st year, 5.8 million € in the 2nd year
and 13.9 million € in the 3rd year. 25 €/unit is charged by the contract manufacturer which will
produce the gross profit for the 3 years as 1.3, 5.0, 12.2, respectively. Such a hypothesis will
generate an ROI of 7 and a total of 35 new jobs.

Company: Vita Sentry is a medical device company that has developed health condition diagnostics
via monitoring inner diameter of arterioles. It has developed a non-invasive optical technology,
which for the first time measures the inner diameter, cross section, degree of change, and level of
stiffness for small blood vessels - arterioles.
The Vita Sentry team comprises of Elon Rachman, CEO and a 30-year entrepreneur in the
technology industry. He has an extensive experience in communication and software systems
engineering (IDF) and holds a B.SC. in Electronics degree from the Technion, Israel Institute of
Technology, Israel, Reuven Gladshtein, Inventor, CTO, who has a 27 years of experience as an
R&D Engineer & 15 years of vast experience in Biomed startup. He is also the author of 4 patents
in the Biomed field and holds the degree of MSEE from the Moscow’s Technical university for
Communication and Informatics and Space Research Institute, Moscow, and Professor Avi A.
Weinbroum, MD, Chief Medical Officer - Professor of Anesthesia & Intensive care medicine. He
has also authored more than 200 scientific & medical publications. And was the former head of the
Department Of Anesthesiology and CCM, The Sackler Faculty Of Medicine, Tel Aviv University,
Tel Aviv, Israel. He was also the former head of the Post-Anesthesia Care Unit at the Sourasky
Medical Center (2nd largest hospital in Israel), Tel Aviv, Israel, and the previous Director of
Anesthesia Research Laboratory.

References: https://alientt.com/project/bp24/

https://www.sciencedirect.com/topics/medicine-and-dentistry/myogenic-response

https://www.crunchbase.com/organization/vita-sentry

https://finder.startupnationcentral.org/company_page/vita-sentry